Seminar Poster

Speaker:
Professor Wen Liu
Professor, Minjiang Scholar,
School of Pharmaceutical Sciences,
Xiamen University
China

About the Speaker:
劉文，｢閩江學者｣ 特聘教授、博士生導師。其主要專注於癌症的表觀遺傳調控分子機制以及應用研究，在此領域取得了一系列具有重要意義的成果，發表多篇高水平研究論文，包括 Nature、Cell、Cancer Cell、Molecular Cell 等；在抗癌小分子 K-80003 方面的研究成果在國際上具有廣泛的影響力，該小分子獲得了美國 FDA 關於其在晚期結直腸癌中開展臨床實驗的批件。劉教授主持多項課題，入選國家自然科學基金 ｢優秀青年科學基金｣ 項目和福建省自然科學基金 ｢傑出青年科學基金｣ 項目。取得多項榮譽，獲得中國藥學會──賽諾菲青年生物藥物獎和福建省運盛青年科技獎。

Abstract:
While protein arginine methyltransferases (PRMTs) and PRMT-catalysed protein methylation have been well-known to be involved in a myriad of biological processes, their roles in carcinogenesis, particularly in estrogen receptor alpha (ERa)-positive breast cancers, remain incompletely understood. Here we focused on investigating PRMT4 (also called coactivator associated arginine methyltransferase 1, CARM1) in ERa-positive breast cancers due to its high expression and the associated poor prognosis. The team uncovered a “hypermethylation” strategy utilised by enhancer-bound CARM1 in estrogen/ERa-induced gene transcriptional activation, which is critical for the proliferation of ERa -positive breast cancer cells in vitro and tumour growth in mice, suggesting that CARM1 can server as a therapeutic target for breast cancer treatment.

CME Accreditation:
* One CME point for attendance approved by the Medical Council of Hong Kong (MCHK). [ Activity No.: 3650 ]

All are welcome.
For enquiries, please contact Miss Tracy Tang at 3763 6088.